Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding ...

Pharmaceutical giant GSK has won a key part of the regulatory approval needed to roll out its vaccine for respiratory syncytial virus (RSV) to adults aged 50 to 59. The US Food and Drug ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is the first FDA-approved RSV vaccine to help prevent lung and lower airway infection from RSV in people 60 and older. The CDC recommends ...

Specifically, the FDA recently approved Arexvy, the world’s first vaccine to fight RSV in adults aged 60 and older. According to its manufacturer GSK, the single shot provides long-term ...

Soreness/redness/swelling/bruising at the injection site may occur. Muscle aches, joint pain, headache, or tiredness may also occur. If any of these effects last or ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

Historically, the British drugmaker’s R&D returns were dominated by its HIV treatments and Shingrix and Arexvy vaccines, they say. Shares are down 0.9%. ([email protected]) ...